Medios AG continues its dynamic growth in the first nine months 2017

  • Consolidated sales in the first nine months 2017 reach EUR 187.3 million, already surpassing the consolidated sales of full year 2016 significantly
  • Sustained high demand for individualised medicine makes the Management Board confident to increase the sales in the full year to around EUR 230 million as planned

Berlin, 13 November 2017 – Medios AG, one of the leading Specialty Pharma companies in Germany, has continued its dynamic growth in the first nine months 2017 and confirms the sales forecast as well as the earnings forecast for the full year. In the period from January to September, Medios generated consolidated sales of EUR 187.3 million (IFRS), already surpassing the consolidated sales of full year 2016 significantly (prior year EUR 160.4 million, pro-forma IFRS). For the full year 2017, the Management Board still expects consolidated sales of around EUR 230 million. The forecast for consolidated earnings before taxes (EBT) in the amount of EUR 7.0 million up to EUR 7.5 million before special effects remains unchanged. In this context, burdens through growth investments and the consequences of the abolition of cytostatic drug tenderings through the German Act on Strengthening Pharmaceutical Supply in Statutory Health Insurance, which are not yet foreseeable, have already been considered. In contrast, the non-cash special effect through the stock option programme, which was implemented on the basis of the resolution of the Annual General Meeting 2017 in order to incentivise the management team, is not considered. The special effect will cause an extraordinary expense amounting to around EUR 1.1 million in the full year 2017.

Manfred Schneider, CEO of Medios AG: “The sustained high demand for individualised medicine in the first nine months 2017 makes us confident that we will increase our sales by some 44 percent to around 230 million euro as planned. Thereby, we take a further step towards our aim to become the leading provider of Specialty Pharma solutions in Germany.“

In the first nine months 2017, Medios focused on the implementation of the growth strategy. The most important measures included the establishment of the Medios Digital GmbH subsidiary, the purchase of a property in Berlin-Charlottenburg, the successful placement of new shares with institutional investors within a cash capital increase and the purchase of additional clean room capacities in order to accelerate the expansion of the manufacturing capacities for individualised medicine.

About Medios AG

Medios AG is one of the leading Specialty Pharma companies in Germany. As wholesaler for Specialty Pharma drugs and manufacturer of patient-specific medications, Medios covers substantial elements of the supply chain in this field. Specialty Pharma drugs are, in particular, individualised infusions for patients with rare or chronic diseases like cancer, HIV and hepatitis. It is Medios’ aim to provide integrated solutions along the value chain to partners and clients, thereby ensuring an optimal pharmaceutical care for patients.

Medios AG is Germany’s first listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard) and Hamburg-Hannover Stock Exchange.


Kirchhoff Consult AG
Nikolaus Hammerschmidt
Borselstraße 20
22765 Hamburg

Telephone: +49 40 60918618
Fax: +49 40 60918660

This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward- looking statements contained in this notification.